title: Natural killer cell activity in untreated and treated dogs with lymphoma.
abstract: Natural killer (NK) cell activity and function were determined for 11 untreated and treated dogs with lymphoma. Concurrent chromium release and single cell binding assays, methods used to measure overall cytotoxic activity and that from individual cells, respectively, were performed at effector-to-target cell ratios of 50:1 and 100:1, with incubation periods of 12 and 16 hours. Significant reduction was achieved in overall activity for untreated dogs, using a 16-hour incubation period and an effector-to-target ratio of 100:1 (P less than 0.05). Decreased activity (P less than 0.025) was also achieved for those dogs that were administered combination chemotherapy, consisting of such drugs as cyclophosphamide, vincristine, prednisone, and doxorubicin. There was no significant difference in binding or cytotoxic activity by individual cells in the untreated or treated dogs, compared with the healthy controls. Short- or long-term treatment with glucocorticoids did not influence overall NK cll activity or individual cell cytotoxicity. The overall cytotoxic activity in untreated dogs was reduced, but these dogs had relatively normal numbers of NK cells compared with paracontrols. This suggests that a defect in recycling or the ability to kill targets repetitively, may be involved. A similar defect was found in NK cells of dogs treated aggressively with combination chemotherapy.
authors.affiliation: Department of Pathology, College of Veterinary Medicine, Michigan State University, East Lansing 48824.
authors.forename: R E
authors.initials: RE
authors.lastname: Raskin
authors.forename: H W
authors.initials: HW
authors.lastname: Tvedten
authors.forename: R W
authors.initials: RW
authors.lastname: Bull
authors.forename: S E
authors.initials: SE
authors.lastname: Crow
authors.forename: R W
authors.initials: RW
authors.lastname: Dunstan
authors.forename: J D
authors.initials: JD
authors.lastname: Krehbiel
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003602:Cytotoxicity, Immunologic; D004283:Dog Diseases / Q000188:drug therapy / Q000276:immunology*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage; D005938:Glucocorticoids / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology*; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D005938:Glucocorticoids; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone